⁍ The 2-1 decision was issued by the U.S. Federal Circuit Court of Appeals in Washington, D.C

– A federal appeals court in Washington, DC, on Friday reinstated a 2017 jury verdict that required Teva Pharmaceutical Industries Ltd to pay GlaxoSmithKline Plc more than $235 million for infringing a patent for its blood pressure drug Coreg, Reuters reports. The 2-1 decision was issued by the US Federal Circuit Court of Appeals in Washington, DC. According to the Wall Street Journal, a jury found Teva had infringed on a patent for Coreg held by GlaxoSmithKline, which makes Coreg, a blood pressure drug. A lower court had set the amount at $235 million. Teva appealed.